Glenmede Trust’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Glenmede Trust’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,300	Closed	-$13K	–	2573
2018 Q1	$13K	Hold	3,300	–	–	﹤0.01%	2112
2017 Q4	$13K	Sell	3,300 -300	-8%	-$1.3K	﹤0.01%	2112
2017 Q3	$16K	Sell	3,600 -9,300	-72%	-$37.7K	﹤0.01%	2048
2017 Q2	$118K	Hold	12,900	–	–	﹤0.01%	1342
2017 Q1	$118K	Sell	12,900 -10,000	-44%	-$87.8K	﹤0.01%	1342
2016 Q4	$176K	Hold	22,900	–	–	﹤0.01%	1243
2016 Q3	$261K	Sell	22,900 -5,800	-20%	-$67.5K	﹤0.01%	1124
2016 Q2	$353K	Hold	28,700	–	–	﹤0.01%	1019
2016 Q1	$290K	Hold	28,700	–	–	﹤0.01%	1064
2015 Q4	$646K	Hold	28,700	–	–	﹤0.01%	843
2015 Q3	$476K	Hold	28,700	–	–	﹤0.01%	913
2015 Q2	$645K	Hold	28,700	–	–	﹤0.01%	854
2015 Q1	$739K	Hold	28,700	–	–	0.01%	838
2014 Q4	$624K	Hold	28,700	–	–	﹤0.01%	841
2014 Q3	$543K	Hold	28,700	–	–	﹤0.01%	850
2014 Q2	$668K	Hold	28,700	–	–	0.01%	792
2014 Q1	$965K	Hold	28,700	–	–	0.01%	703
2013 Q4	$847K	Hold	28,700	–	–	0.01%	720
2013 Q3	$439K	Buy	+28,700	New	+$532K	0.01%	858

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Glenmede Trust's OMED Position: Q2 2018 in Review

Glenmede Trust sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2018, closing a stake of 3,300 shares — an estimated $13K sold.

Glenmede Trust first reported a position in OMED in Q3 2013 and held it in 19 quarters. The position peaked at $965K in Q1 2014. 63 funds tracked by Wall St. Rank hold OMED as of Q2 2018.

Glenmede Trust reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Glenmede Trust sold 3,300 OncoMed Pharmaceuticals, Inc. shares in Q2 2018, an estimated $13K.
Glenmede Trust first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 19 quarters.
Glenmede Trust's OncoMed Pharmaceuticals, Inc. position peaked at $965K in Q1 2014.
63 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2018.

Based on Glenmede Trust's 13F filing for Q2 2018, filed 15 Aug 2018.